Caplin Point Laboratories has reported a strong financial performance for the fourth quarter (Q4) of FY25, with net profit rising 17.3% year-on-year (YoY) to ₹142.6 crore. The company also recorded an 11% revenue growth, reaching ₹503 crore, driven by steady business momentum and improved cost efficiency.
Financial Highlights
- Net Profit: ₹142.6 crore, up 17.3% YoY.
- Revenue: ₹503 crore, reflecting an 11% growth.
- EBITDA: ₹168 crore, marking a 15.7% increase.
- Margins: Expanded to 33.5%, up from 32% in the previous year.
- Dividend: ₹3 per share (150%), with a record date set for May 30, 2025.
Growth Outlook & Expansion Plans
Caplin Point expects 13–14% topline growth in FY26, with EBITDA margins projected to remain within the 32–34% range. The company is focusing on expanding its presence in the U.S. market, strengthening its oncology portfolio, and entering Brazil and Mexico.
Stock Performance
Following the earnings announcement, Caplin Point Laboratories’ stock was trading 1.29% lower at ₹1,989.80 on the BSE.
For more updates on Caplin Point Laboratories and pharmaceutical sector trends, stay tuned!
